Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
905 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01113957 | A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer | completed | Phase 2 | 168 | AbbVie (prior sponsor, Abbott)INDUSTRY | 8 | Jun 6, 2018 | clinicaltrials |
| NCT02273973 | A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI) | completed | Phase 2 | 334 | Genentech, Inc.INDUSTRY | 22 | May 21, 2018 | clinicaltrials |
| NCT00266877 | Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 172 | Puma Biotechnology, Inc.INDUSTRY | 5 | Apr 13, 2018 | clinicaltrials |
| NCT01030536 | Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL) | completed | Phase 1 / Phase 2 | 23 | MedImmune LLCINDUSTRY | 2 | Apr 9, 2018 | clinicaltrials |
| NCT01453205 | A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | completed | Phase 2 | 187 | MedImmune LLCINDUSTRY | 11 | Mar 12, 2018 | clinicaltrials |
| NCT00299494 | Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL) | completed | Phase 1 / Phase 2 | 119 | PfizerINDUSTRY | 13 | Mar 8, 2018 | clinicaltrials |
| NCT00360347 | A Study of Mircera in Anemic Patients With Multiple Myeloma | completed | Phase 1 / Phase 2 | — | Hoffmann-La RocheINDUSTRY | 2 | Mar 1, 2018 | clinicaltrials |
| NCT01472887 | SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients(STARLYTE) | completed | Phase 2 | 61 | SanofiINDUSTRY | 9 | Jan 25, 2018 | clinicaltrials |
| NCT02701517 | Cyclosporine Plus Methotrexate or Alemtuzumab | terminated | Phase 2 | 72 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 2 | Dec 29, 2017 | clinicaltrials |
| NCT00822094 | Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML) | completed | Phase 2 | 126 | Jazz PharmaceuticalsINDUSTRY | 4 | Nov 24, 2017 | clinicaltrials |
| NCT01004003 | Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 2 | 125 | Boehringer IngelheimINDUSTRY | 8 | Oct 26, 2017 | clinicaltrials |
| NCT00101998 | Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication | completed | Phase 2 | 233 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 26 | Aug 30, 2017 | clinicaltrials |
| NCT01991210 | A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC) | terminated | Phase 2 | 95 | Genentech, Inc.INDUSTRY | 7 | Aug 21, 2017 | clinicaltrials |
| NCT00545688 | A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer. | completed | Phase 2 | 417 | Hoffmann-La RocheINDUSTRY | 18 | Aug 15, 2017 | clinicaltrials |
| NCT01779791 | A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma | completed | Phase 2 | 110 | Janssen Research & Development, LLCINDUSTRY | 9 | Jul 18, 2017 | clinicaltrials |
| NCT02016534 | Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors | terminated | Phase 2 | 60 | AmgenINDUSTRY | 18 | Jul 2, 2017 | clinicaltrials |
| NCT02040662 | Comparison of Efficacy of Paravertebral and Epidural Analgesia After Videothoracoscopic Lung Lobectomy | completed | Phase 2 | 120 | Pulmonary Hospital ZakopaneOTHER | 1 | Jun 12, 2017 | clinicaltrials |
| NCT01440374 | A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia(ASPIRE) | completed | Phase 2 | 162 | Novartis PharmaceuticalsINDUSTRY | 22 | Jun 5, 2017 | clinicaltrials |
| NCT01013740 | Lapatinib in Combination With Vinorelbine(VITAL) | completed | Phase 2 | 112 | Novartis PharmaceuticalsINDUSTRY | 10 | May 31, 2017 | clinicaltrials |
| NCT01466153 | A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 183 | MedImmune LLCINDUSTRY | 8 | May 31, 2017 | clinicaltrials |
| NCT01288573 | A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone | completed | Phase 1 / Phase 2 | 46 | Genzyme, a Sanofi CompanyINDUSTRY | 12 | May 16, 2017 | clinicaltrials |
| NCT01641939 | A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer | terminated | Phase 2 / Phase 3 | 415 | Hoffmann-La RocheINDUSTRY | 28 | May 12, 2017 | clinicaltrials |
| NCT00413192 | E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma | completed | Phase 2 | 128 | Eisai Inc.INDUSTRY | 5 | Apr 26, 2017 | clinicaltrials |
| NCT00384176 | First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX(HORIZON III) | completed | Phase 2 / Phase 3 | 1,814 | AstraZenecaINDUSTRY | 28 | Apr 14, 2017 | clinicaltrials |
| NCT00102726 | SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving Chemotherapy | completed | Phase 2 | 183 | GlaxoSmithKlineINDUSTRY | 19 | Mar 23, 2017 | clinicaltrials |
| NCT01357655 | Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923) | terminated | Phase 2 | 70 | Bristol-Myers SquibbINDUSTRY | 8 | Mar 14, 2017 | clinicaltrials |
| NCT01316263 | A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors | terminated | Phase 2 | 21 | Eli Lilly and CompanyINDUSTRY | 6 | Mar 9, 2017 | clinicaltrials |
| NCT01401166 | Participant Preference of Subcutaneous (SC) Versus Intravenous (IV) Herceptin (Trastuzumab) in Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer(PrefHER) | completed | Phase 2 | 488 | Hoffmann-La RocheINDUSTRY | 12 | Mar 6, 2017 | clinicaltrials |
| NCT00089999 | Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer | completed | Phase 2 | 138 | GlaxoSmithKlineINDUSTRY | 11 | Feb 28, 2017 | clinicaltrials |
| NCT01817738 | Trial of RNActive®-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate Cancer | terminated | Phase 1 / Phase 2 | 197 | CureVacINDUSTRY | 8 | Feb 17, 2017 | clinicaltrials |
| NCT01667536 | A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology | completed | Phase 2 | 105 | Molecular Insight Pharmaceuticals, Inc.INDUSTRY | 8 | Feb 7, 2017 | clinicaltrials |
| NCT01040832 | EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 107 | EMD SeronoINDUSTRY | 8 | Jan 30, 2017 | clinicaltrials |
| NCT01870609 | Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma(COMMAND) | terminated | Phase 2 | 344 | Verastem, Inc.INDUSTRY | 15 | Jan 30, 2017 | clinicaltrials |
| NCT01520922 | Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL) | completed | Phase 2 | 99 | Novartis PharmaceuticalsINDUSTRY | 8 | Jan 19, 2017 | clinicaltrials |
| NCT00842712 | Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC)(CERTO) | completed | Phase 2 | 232 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 8 | Jan 13, 2017 | clinicaltrials |
| NCT01383148 | Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer(TIME) | terminated | Phase 2 / Phase 3 | 222 | TransgeneINDUSTRY | 10 | Jan 5, 2017 | clinicaltrials |
| NCT02107378 | Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma | terminated | Phase 2 | 22 | SOTIO a.s.INDUSTRY | 3 | Nov 30, 2016 | clinicaltrials |
| NCT02465814 | Assess Safety and Efficacy of Vilaprisan in Patients With Uterine Fibroids(ASTEROID 2) | completed | Phase 2 | 120 | BayerINDUSTRY | 16 | Nov 22, 2016 | clinicaltrials |
| NCT02748213 | A Study of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast Cancer | completed | Phase 2 | 225 | Hoffmann-La RocheINDUSTRY | 15 | Nov 22, 2016 | clinicaltrials |
| NCT01087151 | A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 118 | Genentech, Inc.INDUSTRY | 12 | Nov 2, 2016 | clinicaltrials |
| NCT00813605 | QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma | completed | Phase 2 | 155 | NantCell, Inc.INDUSTRY | 10 | Oct 27, 2016 | clinicaltrials |
| NCT01454089 | A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer | completed | Phase 2 | 183 | Achieve Life SciencesINDUSTRY | 7 | Oct 7, 2016 | clinicaltrials |
| NCT00289627 | A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma | completed | Phase 2 | 155 | Bristol-Myers SquibbINDUSTRY | 10 | Sep 28, 2016 | clinicaltrials |
| NCT01755624 | Effect of TTFields (150kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-5 Brain Metastases Following Optimal Standard Local Treatment (COMET) | unknown | Phase 2 | 18 | NovoCure Ltd.INDUSTRY | 5 | Sep 21, 2016 | clinicaltrials |
| NCT00688753 | RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe(MACS0460) | completed | Phase 2 | 92 | Novartis PharmaceuticalsINDUSTRY | 6 | Sep 2, 2016 | clinicaltrials |
| NCT00446069 | A Efficacy and Safety Trial of Controlled Release (CR) Morphine in Cancer Patients | completed | Phase 2 | 36 | Egalet LtdINDUSTRY | 2 | Aug 29, 2016 | clinicaltrials |
| NCT01399684 | A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer | completed | Phase 2 | 127 | Genentech, Inc.INDUSTRY | 5 | Aug 26, 2016 | clinicaltrials |
| NCT00404703 | A Study of Avastin (Bevacizumab) in Combination With Platinum-Based Chemotherapy in Patients With Advanced or Recurrent Squamous Non-Small Cell Lung Cancer | terminated | Phase 2 | 37 | Hoffmann-La RocheINDUSTRY | 10 | Aug 24, 2016 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials